In vitro exposure of bacteria to antimicrobial impregnated-central venous catheters does not directly lead to the emergence of antimicrobial resistance

Chest

Volumn 126, Issue 5, 2004, Pages 1628-1635

  Munson, Erik L ^a   Heard, Stephen O ^b   Doern, Gary V ^c  

^a Medical Science Laboratories   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antibiotic impregnated catheters; Antimicrobrial resistance; Catheter related infection; Minocycline; Rifampin

Indexed keywords

AGAR; MINOCYCLINE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; CATHETER INFECTION; CENTRAL VENOUS CATHETER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; IN VITRO STUDY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 8744314896     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.5.1628     Document Type: Article

References (22)

1. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391-402
2. Digiovine B, Chenoweth C, Watts C, et al. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999; 160:976-981
3. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15:231-238
4. Maki DG, Mermel LA, Kluger D, et al. The efficacy of a chlorhexidine-impregnated sponge (Biopatch) for the prevention of intravascular catheter-related infection: a prospective, randomized, controlled, multicenter study. Presented at: 40th Inter-science Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000; Toronto, Canada
5. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338:339-343
6. Maki DG, Stolz SM, Wheeler S, et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997; 127:257-266
7. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters: Catheter Study Group. N Engl J Med 1999; 340:1-8
8. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial; The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127:267-274
9. Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother 2001; 7:589-598
10. Sherertz RJ, Forman DM, Solomon DD. Efficacy of dicloxacillin-coated polyurethane catheters in preventing subcutaneous Staphylococcus aureus infection in mice. Antimicrob Agents Chemother 1989; 33:1174-1178
11. Chatzinikolaou I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 2003; 115:352-357
12. Hanna HA, Raad II, Hackett B, et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest 2003; 124:1030-1038
13. Raad I, Darouiche R, Hachem R, et al. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996; 173:418-424
14. Raad I, Darouiche R, Hachem R, et al. Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother 1995; 39:2397-2400
15. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol 2001; 22:640-646
16. Sande MA. The use of rifampin in the treatment of nontuberculous infections: an overview. Rev Infect Dis 1983; 5(suppl 3):S399-S401
17. Mandell GL. The antimicrobial activity of rifampin: emphasis on the relation to phagocytes. Rev Infect Dis 1983; 5(suppl 3):S463-S467
18. Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29:495-502
19. Fluit AC, Jones ME, Schmitz FJ, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30:454-460
20. Fluit AC, Wielders CL, Verhoef J, et al. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001; 39:3727-3732
21. Bach A, Schmidt H, Bottiger B, et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemother 1996; 37:315-322
22. Marik PE, Abraham G, Careau P, et al. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med 1999; 27: 1128-1131